OSR Holdings, Inc. (OSRH)
- Previous Close
1.6300 - Open
1.5200 - Bid 1.5700 x 100
- Ask 1.6700 x 100
- Day's Range
1.5200 - 1.5300 - 52 Week Range
1.0200 - 13.4000 - Volume
3,984 - Avg. Volume
3,131,541 - Market Cap (intraday)
29.494M - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
www.osr-holdings.comRecent News: OSRH
View MorePerformance Overview: OSRH
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OSRH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OSRH
View MoreValuation Measures
Market Cap
31.42M
Enterprise Value
34.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.41
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
-148.95k
Net Income Avi to Common (ttm)
-10.45M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.6M
Total Debt/Equity (mrq)
3.61%
Levered Free Cash Flow (ttm)
--